Updates are available Correction dated 2022-06-08
Click to view Correction: https://doi.org/10.1186/s12888-022-03975-3
Updates are available Correction dated 2022-03-07
Click to view Correction: https://doi.org/10.1186/s12888-022-03798-2
-
Authors
McCue, Maggie http://orcid.org/0000-0003-1953-1795
Sarkey, Sara
Eramo, Anna
François, Clement
Parikh, Sagar V.
-
Funding
Funding for this research was provided by:
Takeda Pharmaceuticals U.S.A., Inc. (N/A)
Lundbeck LLC (N/A)
- License Information
-
More Information
Article History
Received: 13 October 2020
Accepted: 6 October 2021
First Online: 11 December 2021
Change Date: 8 June 2022
Change Type: Correction
Change Details: A Correction to this paper has been published:
Change Details: https://doi.org/10.1186/s12888-022-03975-3
Change Date: 7 March 2022
Change Type: Correction
Change Details: A Correction to this paper has been published:
Change Details: https://doi.org/10.1186/s12888-022-03798-2
Declarations
:
: The study was conducted in accordance with the Declaration of Helsinki and ICH guidelines, and all patients provided written informed consent before participating in the study. The study protocol was approved by the institutional review board (IRB) at all participating sites on behalf of the Copernicus Group Independent Review Board, a WIRD-Copernicus Group Company (IRB tracking no. QUI1–16-522).
: Not applicable.
: MM and SS are employees of Takeda Pharmaceuticals U.S.A., Inc. AE and CF were employees of Lundbeck, LLC, at the time of this study. SVP is a consultant to Takeda and Sunovion, has a research contract with Assurex Health, Inc., and owns shares in Mensante Corporation.
